Summary (tl;dr)

Nearly 90,000 bottles of Children's Ibuprofen Oral Suspension have been recalled nationwide in the United States due to the confirmed presence of a foreign substance, including gel-like masses and black particles, in the medication.

Essential Background

Children's ibuprofen is a common over-the-counter medication used to reduce fever and pain in children. The quality and safety of such medications are critical due to their intended use in vulnerable populations. Pharmaceutical companies are responsible for ensuring their products meet stringent quality standards set by regulatory bodies like the U.S. Food and Drug Administration (FDA).

The Full Story

Strides Pharma Inc. initiated a voluntary recall on March 2, 2026, for approximately 89,592 bottles of Children's Ibuprofen Oral Suspension. This recall, classified as a Class II recall by the FDA on March 16, 2026, was prompted by customer complaints reporting the discovery of a gel-like mass and black particles within the liquid medication. The affected products are 4 fl. oz. (120 mL) bottles of Children's Ibuprofen Oral Suspension, USP, 100 mg per 5mL, with specific lot numbers 7261973A and 7261974A, and an expiration date of January 31, 2027. The medication was manufactured by Strides Pharma Inc. in India for Taro Pharmaceuticals U.S.A., Inc., based in Hawthorne, New York, and distributed across the United States.

Why It Matters

This recall is significant because it involves medication given to children, raising concerns among parents and caregivers about product safety and efficacy. A Class II recall indicates that exposure to the contaminated product could lead to temporary or medically reversible adverse health consequences, with a remote possibility of serious harm. While the FDA has not reported any serious adverse health effects related to this particular recall, the presence of foreign substances in medication for children is a serious quality control issue, prompting consumers to check their medicine cabinets and discontinue use of the affected lots.

Geographic Location

• Bridgewater, Somerset County, New Jersey, United States (location of Strides Pharma Inc. subsidiary that initiated the recall)
• Hawthorne, Westchester County, New York, United States (location of Taro Pharmaceuticals U.S.A., Inc., for whom the product was manufactured)
• United States (nationwide distribution of the recalled product and FDA's jurisdiction)
• India (manufacturing origin by Strides Pharma Inc.)